Vibrio cholerae CVD 103-HgR strain live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Vibrio cholerae CVD 103-HgR strain live antigen
Accession Number
DB14443
Description

Vibrio cholerae CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against Vibrio cholerae serogroup O1.1

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Cholera Vaccine
  • Cholera Vaccine Live Oral
  • Cholera vaccine, live, oral

Pharmacology

Indication

Vibrio cholerae CVD 103-HgR strain live antigen is indicated for active oral immunization against infection caused by Vibrio cholerae serogroup O1 in patients between 18 and 64 years of age.1

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Abatacept.
Acetic acidThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Acetic acid.
Acetyl sulfisoxazoleThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Acetyl sulfisoxazole.
AcyclovirThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alemtuzumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take separate from meals. Oral cholera vaccines should be administered on an empty stomach. Avoid food or drink for 60 minutes before and after administration.

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Cholera Vaccine Strain 35a-and 41 8000m/ccSuspensionSubcutaneousAventis Pasteur Limited1942-12-312001-07-19Canada flag
VaxchoraKit1200000000 [CFU]/1OralPaxvax, Inc.2016-10-03Not applicableUS flag
Vaxchora1200000000 [CFU]/1OralPaxvax, Inc.2020-02-13Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
V9G528E9E0
CAS number
1704499-30-8

References

General References
  1. FDA Approved Drug Products: Vaxchora (cholera vaccine, live, oral) oral suspension [Link]
RxNav
1812935

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionCholera Vaccination Reaction1
4CompletedPreventionCholera2
4CompletedPreventionCholera / Vibrio Cholerae1
4CompletedPreventionVibrio Cholerae1
4RecruitingBasic ScienceCholera Vaccination1
4RecruitingBasic ScienceTyphoid and/or Cholera Vaccination1
4RecruitingPreventionCholera / Vibrio Cholerae Infection1
3CompletedPreventionCholera1
3CompletedPreventionCholera / Diarrhea / Vibrio Infections1
3CompletedPreventionPrevention Harmful Effects1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionSubcutaneous
KitOral1200000000 [CFU]/1
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on July 05, 2018 12:02 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates